BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, Collins M, Chaput N, Robert C, Carbonnel F. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 2018;67:2056-67. [DOI: 10.1136/gutjnl-2018-316948] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 24.7] [Reference Citation Analysis]
Number Citing Articles
1 Reese SW, Marchese M, McNabb-Baltar J. Insights from Pharmacovigilance: Gastrointestinal-Related Immune Checkpoint Inhibitor Adverse Events. Gastroenterology 2020;159:1195-1200.e1. [PMID: 32681919 DOI: 10.1053/j.gastro.2020.06.093] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Sebastian S, Neilaj S. Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment? Therap Adv Gastroenterol 2019;12:1756284818817293. [PMID: 30643542 DOI: 10.1177/1756284818817293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
3 Alhatem A, Patel K, Eriksen B, Bukhari S, Liu C. Nivolumab-Induced Concomitant Severe Upper and Lower Gastrointestinal Immune-Related Adverse Effects. ACG Case Rep J 2019;6:e00249. [PMID: 32309466 DOI: 10.14309/crj.0000000000000249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Poels K, van Leent MMT, Boutros C, Tissot H, Roy S, Meerwaldt AE, Toner YCA, Reiche ME, Kusters PJH, Malinova T, Huveneers S, Kaufman AE, Mani V, Fayad ZA, de Winther MPJ, Marabelle A, Mulder WJM, Robert C, Seijkens TTP, Lutgens E. Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis. JACC CardioOncol 2020;2:599-610. [PMID: 34396271 DOI: 10.1016/j.jaccao.2020.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
5 Chatzidionysiou K, Liapi M, Tsakonas G, Gunnarsson I, Catrina A. Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift? Clin Rheumatol 2021;40:1687-95. [PMID: 32989505 DOI: 10.1007/s10067-020-05420-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kadokawa Y, Takagi M, Yoshida T, Tatsumi A, Fujita K, Inoue T, Ohe S, Nakai Y, Yamamoto S, Otsuka T, Ishihara R, Isei T, Kumagai T, Nishimura K, Imamura F. Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study. Mol Clin Oncol 2021;14:65. [PMID: 33680456 DOI: 10.3892/mco.2021.2227] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Xu W, Liu K, Chen M, Sun JY, McCaughan GW, Lu XJ, Ji J. Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives.Ther Adv Med Oncol. 2019;11:1758835919862692. [PMID: 31384311 DOI: 10.1177/1758835919862692] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 18.0] [Reference Citation Analysis]
8 Yang J, Wu J, Li Y, Zhang Y, Cho WC, Ju X, van Schothorst EM, Zheng Y. Gut bacteria formation and influencing factors. FEMS Microbiol Ecol 2021;97:fiab043. [PMID: 33705527 DOI: 10.1093/femsec/fiab043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Talbot S, MacLaren V, Lafferty H. Sclerosing cholangitis in a patient treated with nivolumab. BMJ Case Rep 2021;14:e241700. [PMID: 34049893 DOI: 10.1136/bcr-2021-241700] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020;115:202-210. [PMID: 31922959 DOI: 10.14309/ajg.0000000000000497] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
11 Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH, Calabrese L. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol 2020;17:504-15. [DOI: 10.1038/s41571-020-0352-8] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 51.0] [Reference Citation Analysis]
12 Li Y, Kang X, Wang H, Guo X, Zhou J, Duan L, Si X, Zhang L, Liu X, Qian J, Zhang L. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. Thorac Cancer 2020;11:829-34. [PMID: 32107847 DOI: 10.1111/1759-7714.13338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Chao G, Li X, Ji Y, Zhu Y, Li N, Zhang N, Feng Z, Niu M. CTLA-4 regulates T follicular regulatory cell differentiation and participates in intestinal damage caused by spontaneous autoimmunity. Biochemical and Biophysical Research Communications 2018;505:865-71. [DOI: 10.1016/j.bbrc.2018.09.182] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Sehrawat N, Yadav M, Singh M, Kumar V, Sharma VR, Sharma AK. Probiotics in microbiome ecological balance providing a therapeutic window against cancer. Semin Cancer Biol 2021;70:24-36. [PMID: 32574811 DOI: 10.1016/j.semcancer.2020.06.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
15 Sakurai T, De Velasco MA, Sakai K, Nagai T, Nishiyama H, Hashimoto K, Uemura H, Kawakami H, Nakagawa K, Ogata H, Nishio K, Kudo M. Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis. Mol Oncol 2021. [PMID: 34270845 DOI: 10.1002/1878-0261.13062] [Reference Citation Analysis]
16 Gaucher F, Kponouglo K, Rabah H, Bonnassie S, Ossemond J, Pottier S, Jardin J, Briard-Bion V, Marchand P, Blanc P, Jeantet R, Jan G. Propionibacterium freudenreichii CIRM-BIA 129 Osmoadaptation Coupled to Acid-Adaptation Increases Its Viability During Freeze-Drying. Front Microbiol 2019;10:2324. [PMID: 31681198 DOI: 10.3389/fmicb.2019.02324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
17 Saab S, Zalzale H, Rahal Z, Khalifeh Y, Sinjab A, Kadara H. Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Front Immunol 2020;11:159. [PMID: 32117295 DOI: 10.3389/fimmu.2020.00159] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
18 Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(8): 772-798 [PMID: 34457186 DOI: 10.4251/wjgo.v13.i8.772] [Reference Citation Analysis]
19 Iwamoto M, Kato K, Moriyama M, Yamaguchi K, Takahashi S. Remission of ulcerative colitis flare-up induced by nivolumab. Int J Colorectal Dis 2020;35:1791-5. [PMID: 32458394 DOI: 10.1007/s00384-020-03638-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology 2020;76:233-43. [PMID: 31361907 DOI: 10.1111/his.13963] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 13.5] [Reference Citation Analysis]
21 Miyashita A, Fukushima S, Tsukamoto H, Itai H, Miyamoto H, Nakahara S, Kubo Y, Kimura T, Kuriyama H, Ihn H. Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis. J Dermatol 2019;46:e339-41. [PMID: 30908699 DOI: 10.1111/1346-8138.14857] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Zhao Z, Zheng L, Chen W, Weng W, Song J, Ji J. Delivery strategies of cancer immunotherapy: recent advances and future perspectives. J Hematol Oncol 2019;12:126. [PMID: 31779642 DOI: 10.1186/s13045-019-0817-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
23 Zang K, Hui L, Wang M, Huang Y, Zhu X, Yao B. TIM-3 as a Prognostic Marker and a Potential Immunotherapy Target in Human Malignant Tumors: A Meta-Analysis and Bioinformatics Validation. Front Oncol 2021;11:579351. [PMID: 33692946 DOI: 10.3389/fonc.2021.579351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
24 Saleh K, Bellanger C, Garcia G, Classe M, Even C. Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait. Eur J Cancer 2021;145:155-7. [PMID: 33476895 DOI: 10.1016/j.ejca.2020.12.020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer 2019;7:226. [PMID: 31439050 DOI: 10.1186/s40425-019-0711-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 18.5] [Reference Citation Analysis]
26 Londoño MC, Reig M; RETOINMUNO Multidisciplinary Group. Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. Cancers (Basel) 2020;12:E3446. [PMID: 33228219 DOI: 10.3390/cancers12113446] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
27 Fessas P, Possamai LA, Clark J, Daniels E, Gudd C, Mullish BH, Alexander JL, Pinato DJ. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology 2020;159:167-77. [PMID: 31646612 DOI: 10.1111/imm.13141] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
28 Badran YR, Shih A, Leet D, Mooradian MJ, Coromilas A, Chen J, Kem M, Zheng H, Borowsky J, Misdraji J, Mino-Kenudson M, Dougan M. Immune checkpoint inhibitor-associated celiac disease. J Immunother Cancer 2020;8:e000958. [PMID: 32581063 DOI: 10.1136/jitc-2020-000958] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
29 Criscitiello C, Corti C, Pravettoni G, Curigliano G. Managing side effects of immune checkpoint inhibitors in breast cancer. Crit Rev Oncol Hematol 2021;162:103354. [PMID: 34029683 DOI: 10.1016/j.critrevonc.2021.103354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Esfahani K. Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis. J Immunother Cancer 2018;6:154. [PMID: 30577825 DOI: 10.1186/s40425-018-0480-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Hone Lopez S, Kats-Ugurlu G, Renken RJ, Buikema HJ, de Groot MR, Visschedijk MC, Dijkstra G, Jalving M, de Haan JJ. Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis. Virchows Arch 2021. [PMID: 34338882 DOI: 10.1007/s00428-021-03170-x] [Reference Citation Analysis]
32 Carroll CSE, Andrew ER, Malik L, Elliott KF, Brennan M, Meyer J, Hintze A, Almonte AA, Lappin C, MacPherson P, Schulte KM, Dahlstrom JE, Tamhane R, Neeman T, Herbert EW, Orange M, Yip D, Allavena R, Fahrer AM. Simple and effective bacterial-based intratumoral cancer immunotherapy. J Immunother Cancer 2021;9:e002688. [PMID: 34531247 DOI: 10.1136/jitc-2021-002688] [Reference Citation Analysis]
33 Sanders D, Webber D, Chatur N. Enteritis with immune checkpoint inhibitor use. CMAJ 2019;191:E1106. [PMID: 31591098 DOI: 10.1503/cmaj.190244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
34 Lo YC, Price C, Blenman K, Patil P, Zhang X, Robert ME. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy. Am J Clin Pathol 2021;156:214-28. [PMID: 33555016 DOI: 10.1093/ajcp/aqaa217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Sun S, Luo L, Liang W, Yin Q, Guo J, Rush AM, Lv Z, Liang Q, Fischbach MA, Sonnenburg JL, Dodd D, Davis MM, Wang F. Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade. Proc Natl Acad Sci U S A 2020;117:27509-15. [PMID: 33077598 DOI: 10.1073/pnas.1921223117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
36 Almonte AA, Rangarajan H, Yip D, Fahrer AM. How does the gut microbiome influence immune checkpoint blockade therapy? Immunol Cell Biol 2021;99:361-72. [PMID: 33147357 DOI: 10.1111/imcb.12423] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Beck TN, Kudinov AE, Dulaimi E, Boumber Y. Case report: reinitiating pembrolizumab treatment after small bowel perforation. BMC Cancer 2019;19:379. [PMID: 31018834 DOI: 10.1186/s12885-019-5577-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
38 Sasson SC, Slevin SM, Cheung VTF, Nassiri I, Olsson-Brown A, Fryer E, Ferreira RC, Trzupek D, Gupta T, Al-Hillawi L, Issaias ML, Easton A, Campo L, FitzPatrick MEB, Adams J, Chitnis M, Protheroe A, Tuthill M, Coupe N, Simmons A, Payne M, Middleton MR, Travis SPL, Fairfax BP, Klenerman P, Brain O; Oxford Inflammatory Bowel Disease Cohort Investigators. Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis. Gastroenterology 2021:S0016-5085(21)03139-5. [PMID: 34147519 DOI: 10.1053/j.gastro.2021.06.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Abu-Sbeih H, Ali FS, Wang Y. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. Curr Opin Gastroenterol 2020;36:25-32. [PMID: 31609734 DOI: 10.1097/MOG.0000000000000593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
40 Chao G, Li X, Ji Y, Zhu Y, Li N, Zhang N, Feng Z, Niu M. MiR-155 controls follicular Treg cell-mediated humoral autoimmune intestinal injury by inhibiting CTLA-4 expression. Int Immunopharmacol 2019;71:267-76. [PMID: 30927737 DOI: 10.1016/j.intimp.2019.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
41 Furuta Y, Miyamoto H, Naoe H, Shimoda M, Hinokuma Y, Miyamura T, Miyashita A, Fukushima S, Tanaka M, Sasaki Y. Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis. Case Rep Gastroenterol 2020;14:103-9. [PMID: 32231510 DOI: 10.1159/000506186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
42 Parthymos I, Liamis G, Dounousi E, Pentheroudakis G, Mauri D, Zarkavelis G, Florentin M. Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice. Crit Rev Oncol Hematol 2020;151:102979. [PMID: 32480349 DOI: 10.1016/j.critrevonc.2020.102979] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
43 Sanz-Segura P, García-Cámara P, Fernández-Bonilla E, Arbonés-Mainar JM, Bernal Monterde V. Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: A descriptive observational study. Gastroenterol Hepatol 2021;44:261-8. [PMID: 33153772 DOI: 10.1016/j.gastrohep.2020.07.009] [Reference Citation Analysis]
44 Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563-80. [PMID: 31092901 DOI: 10.1038/s41571-019-0218-0] [Cited by in Crossref: 343] [Cited by in F6Publishing: 349] [Article Influence: 171.5] [Reference Citation Analysis]
45 Scarpignato C, Bjarnason I. Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition. Curr Gastroenterol Rep. 2019;21:55. [PMID: 31720893 DOI: 10.1007/s11894-019-0726-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
46 Tran AN, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A, Ciarleglio M, Hung KW, Proctor DD, Price CC, Laine L, Al-Bawardy B. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. J Immunother 2021;44:325-34. [PMID: 34380976 DOI: 10.1097/CJI.0000000000000383] [Reference Citation Analysis]
47 Joseph A, Simonaggio A, Stoclin A, Vieillard-Baron A, Geri G, Oudard S, Michot JM, Lambotte O, Azoulay E, Lemiale V. Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. Ann Intensive Care 2020;10:143. [PMID: 33064239 DOI: 10.1186/s13613-020-00761-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
48 Pezo RC, Wong M, Martin A. Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities. Therap Adv Gastroenterol 2019;12:1756284819870911. [PMID: 31555343 DOI: 10.1177/1756284819870911] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
49 Portenkirchner C, Kienle P, Horisberger K. Checkpoint Inhibitor-Induced Colitis-A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options. Pharmaceuticals (Basel) 2021;14:367. [PMID: 33923423 DOI: 10.3390/ph14040367] [Reference Citation Analysis]
50 Yoshimura K, Saku A, Karayama M, Inui N, Sugimura H, Suda T. Leucine-Rich α2-Glycoprotein as a Potential Biomarker for Immune-related Colitis After Anti-PD-L1 Therapy: A Report of a Case Series. Clin Lung Cancer 2020;21:e516-22. [PMID: 32389505 DOI: 10.1016/j.cllc.2020.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
51 Kunogi Y, Tominaga K, Abe K, Kanazawa M, Tanaka T, Watanabe S, Kondo M, Kanamori A, Iijima M, Goda K, Nozawa Y, Ishida K, Irisawa A. Refractory Immune Checkpoint Inhibitor-Induced Colitis Improved by Tacrolimus: A Case Report. Healthcare (Basel) 2021;9:418. [PMID: 33916353 DOI: 10.3390/healthcare9040418] [Reference Citation Analysis]
52 Collins M, Soularue E, Marthey L, Carbonnel F. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. Clin Gastroenterol Hepatol. 2020;18:1393-1403.e1. [PMID: 32007539 DOI: 10.1016/j.cgh.2020.01.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
53 Cheng P, Shen P, Shan Y, Yang Y, Deng R, Chen W, Lu Y, Wei Z. Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy. Front Cell Dev Biol 2021;9:626045. [PMID: 34568308 DOI: 10.3389/fcell.2021.626045] [Reference Citation Analysis]
54 Fasanello MK, Robillard KT, Boland PM, Bain AJ, Kanehira K. Use of Fecal Microbial Transplantation for Immune Checkpoint Inhibitor Colitis. ACG Case Rep J 2020;7:e00360. [PMID: 32548190 DOI: 10.14309/crj.0000000000000360] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
55 Pesántez D, Seguí E, Ordás I, Viladot M, Arance A. Successful management of refractory immune-mediated enterocolitis with cyclosporine. Eur J Cancer 2020;131:37-9. [PMID: 32278241 DOI: 10.1016/j.ejca.2020.02.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J, Qazi T, Elias R, Vora KB, Ruan AB, Martin-Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi FS, Rahma OE. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020;126:3758-3767. [PMID: 32567084 DOI: 10.1002/cncr.32966] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
57 Yu M, Zhao H, Miao Y, Luo SZ, Xue S. Virtual Evolution of HVEM Segment for Checkpoint Inhibitor Discovery. Int J Mol Sci 2021;22:6638. [PMID: 34205742 DOI: 10.3390/ijms22126638] [Reference Citation Analysis]
58 . Ueg Week 2020 Poster Presentations. United European Gastroenterol j 2020;8:144-887. [DOI: 10.1177/2050640620927345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Perdigoto AL, Kluger H, Herold KC. Adverse events induced by immune checkpoint inhibitors. Curr Opin Immunol 2021;69:29-38. [PMID: 33640598 DOI: 10.1016/j.coi.2021.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
60 Comont T, Belliere J, Sibaud V, Alric L, Meyer N, Mazières J, Caron P, Acket B, Michot JM, Beyne-Rauzy O, Lambotte O. [Immune-related adverse events after immune checkpoints inhibitors in 2019: An update]. Rev Med Interne 2020;41:37-45. [PMID: 31668882 DOI: 10.1016/j.revmed.2019.09.005] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Shivaji UN, Jeffery L, Gui X, Smith SCL, Ahmad OF, Akbar A, Ghosh S, Iacucci M. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol 2019;12:1756284819884196. [PMID: 31723355 DOI: 10.1177/1756284819884196] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
62 Hou Y, Liu Y, Liang S, Ding R, Mo S, Yan D, Li D. The novel target:exosoms derived from M2 macrophage. Int Rev Immunol 2021;40:183-96. [PMID: 32783545 DOI: 10.1080/08830185.2020.1800687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
63 de La Rochefoucauld J, Noël N, Lambotte O. Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. Intern Emerg Med 2020;15:587-98. [PMID: 32144552 DOI: 10.1007/s11739-020-02295-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
64 Liu Y, Wang H, Deng J, Sun C, He Y, Zhou C. Toxicity of tumor immune checkpoint inhibitors-more attention should be paid. Transl Lung Cancer Res 2019;8:1125-33. [PMID: 32010590 DOI: 10.21037/tlcr.2019.11.26] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
65 Teufel A, Zhan T, Härtel N, Bornschein J, Ebert MP, Schulte N. Management of immune related adverse events induced by immune checkpoint inhibition. Cancer Letters 2019;456:80-7. [DOI: 10.1016/j.canlet.2019.04.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]